2:51 PM
 | 
Jan 25, 2018
 |  BC Extra  |  Clinical News

Takeda, Zinfandel’s AD test fails to deliver

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and partner Zinfandel Pharmaceuticals Inc. (Durham, N.C.) discontinued the Phase III TOMORROW trial of 0.8 mg pioglitazone (AD-4833) SR after an interim futility analysis showed the compound was inadequate in delaying the onset of mild cognitive impairment due to Alzheimer’s disease in high-risk subjects. The partners said the decision was...

Read the full 251 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >